<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35325614</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1537-6605</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>109</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of human genetics</Title>
          <ISOAbbreviation>Am J Hum Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.</ArticleTitle>
        <Pagination>
          <StartPage>885</StartPage>
          <EndPage>899</EndPage>
          <MedlinePgn>885-899</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2022.03.004</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0002-9297(22)00100-8</ELocationID>
        <Abstract>
          <AbstractText>Genome-wide association studies (GWASs) of Huntington disease (HD) have identified six DNA maintenance gene loci (among others) as modifiers and implicated a two step-mechanism of pathogenesis: somatic instability of the causative HTT CAG repeat with subsequent triggering of neuronal damage. The largest studies have been limited to HD individuals with a rater-estimated age at motor onset. To capitalize on the wealth of phenotypic data in several large HD natural history studies, we have performed algorithmic prediction by using common motor and cognitive measures to predict age at other disease landmarks as additional phenotypes for GWASs. Combined with imputation with the Trans-Omics for Precision Medicine reference panel, predictions using integrated measures provided objective landmark phenotypes with greater power to detect most modifier loci. Importantly, substantial differences in the relative modifier signal across loci, highlighted by comparing common modifiers at MSH3 and FAN1, revealed that individual modifier effects can act preferentially in the motor or cognitive domains. Individual components of the DNA maintenance modifier mechanisms may therefore act differentially on the neuronal circuits underlying the corresponding clinical measures. In addition, we identified additional modifier effects at the PMS1 and PMS2 loci and implicated a potential second locus on chromosome 7. These findings indicate that broadened discovery and characterization of HD genetic modifiers based on additional quantitative or qualitative phenotypes offers not only the promise of in-human validated therapeutic targets but also a route to dissecting the mechanisms and cell types involved in both the somatic instability and toxicity components of HD pathogenesis.</AbstractText>
          <CopyrightInformation>Copyright © 2022 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jong-Min</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; Medical and Population Genetics Program, the Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, School of Public Health, Yale University, New Haven, CT 06511, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Orth</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Old Age Psychiatry and Psychotherapy, Bern University, 3000 Bern 60, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gillis</LastName>
            <ForeName>Tammy</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siciliano</LastName>
            <ForeName>Jacqueline</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>Eunpyo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mysore</LastName>
            <ForeName>Jayalakshmi Srinidhi</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lucente</LastName>
            <ForeName>Diane</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wheeler</LastName>
            <ForeName>Vanessa C</ForeName>
            <Initials>VC</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seong</LastName>
            <ForeName>Ihn Sik</ForeName>
            <Initials>IS</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McLean</LastName>
            <ForeName>Zachariah L</ForeName>
            <Initials>ZL</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; Medical and Population Genetics Program, the Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mills</LastName>
            <ForeName>James A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Carver College of Medicine, and Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA 52242, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McAllister</LastName>
            <ForeName>Branduff</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lobanov</LastName>
            <ForeName>Sergey V</ForeName>
            <Initials>SV</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Massey</LastName>
            <ForeName>Thomas H</ForeName>
            <Initials>TH</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ciosi</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, U.K.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Landwehrmeyer</LastName>
            <ForeName>G Bernhard</ForeName>
            <Initials>GB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Ulm, Ulm 89081, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paulsen</LastName>
            <ForeName>Jane S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Wisconsin, Madison, 1685 Highland Ave, Madison, WI 53705, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dorsey</LastName>
            <ForeName>E Ray</ForeName>
            <Initials>ER</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shoulson</LastName>
            <ForeName>Ira</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sampaio</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>CHDI Management/CHDI Foundation, Princeton, NJ 08540, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monckton</LastName>
            <ForeName>Darren G</ForeName>
            <Initials>DG</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, U.K.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwak</LastName>
            <ForeName>Seung</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>CHDI Management/CHDI Foundation, Princeton, NJ 08540, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holmans</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jones</LastName>
            <ForeName>Lesley</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>MacDonald</LastName>
            <ForeName>Marcy E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; Medical and Population Genetics Program, the Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Long</LastName>
            <ForeName>Jeffrey D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Carver College of Medicine, and Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA 52242, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gusella</LastName>
            <ForeName>James F</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Medical and Population Genetics Program, the Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address: gusella@helix.mgh.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 NS114065</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 NS082079</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS040068</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS091161</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 NS016367</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS049206</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS119471</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS105709</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Hum Genet</MedlineTA>
        <NlmUniqueID>0370475</NlmUniqueID>
        <ISSNLinking>0002-9297</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CAG repeat</Keyword>
        <Keyword MajorTopicYN="N">DNA maintenance</Keyword>
        <Keyword MajorTopicYN="N">DNA repair</Keyword>
        <Keyword MajorTopicYN="N">Huntington disease</Keyword>
        <Keyword MajorTopicYN="N">age at onset</Keyword>
        <Keyword MajorTopicYN="N">disease modification</Keyword>
        <Keyword MajorTopicYN="N">genetic modifier</Keyword>
        <Keyword MajorTopicYN="N">polyglutamine disease</Keyword>
        <Keyword MajorTopicYN="N">somatic expansion</Keyword>
        <Keyword MajorTopicYN="N">trinucleotide repeat</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of interests J.M.L. serves on the scientific advisory board of GenEdit Inc. V.C.W. is a scientific advisory board member of Triplet Therapeutics Inc., a company developing new therapeutic approaches to address triplet repeat disorders such as Huntington disease and myotonic dystrophy. Her financial interests in Triplet Therapeutics were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. She is a scientific advisory board member of LoQus23 Therapeutics Ltd and has provided paid consulting services to Acadia Pharmaceuticals Inc., Alnylam Inc., and Biogen Inc. She has also received research support from Pfizer Inc. J.A.M. is a paid consultant for PTC Therapeutics Inc. and Behavioral Diagnostics Inc. and has also been a consultant for Wave Life Sciences USA Inc. T.H.M. is an associate member of the scientific advisory board of LoQus23 Therapeutics Ltd. G.B.L. has provided consulting services, advisory board functions, clinical trial services, and lectures for Acadia, Affiris, Allergan, Alnylam, Amarin, AOP Orphan Pharmaceuticals AG, Bayer Pharma AG, Boehringer-Ingelheim, CHDI Foundation, GlaxoSmithKline, Hoffmann-LaRoche, Ipsen, ISIS (Ionis) Pharma, Lundbeck, Neurosearch Inc., Medesis, Medivation, Medtronic, NeuraMetrix, Novartis, Pfizer, Prana Biotechnology, PTC Therapeutics, Raptor, Remix, Sangamo/Shire, Sanofi-Aventis, Siena Biotech, Takeda, Temmler Pharma GmbH, Teva Pharmaceuticals and Triplet Therapeutics. J.S.P. is a paid consultant for Acadia Pharmaceuticals and Wave Life Sciences USA Inc. E.R.D. has received research support from Wave Life Sciences USA Inc. D.G.M. has been a scientific consultant and/or received honoraria/stock options from AMO Pharma, Charles River, LoQus23, Small Molecule RNA, Triplet Therapeutics, and Vertex Pharmaceuticals and held research contracts with AMO Pharma and Vertex Pharmaceuticals within the last 5 years. L.J. is a member of the scientific advisory boards of LoQus23 Therapeutics Ltd and Triplet Therapeutics Inc. and a member of the executive committee of the European Huntington Disease Network. J.D.L. is a paid advisory board member for F. Hoffmann-La Roche Ltd and UniQure, and he is a paid consultant for Triplet Therapeutics, PTC Therapeutics, and Remix Therapeutics. J.F.G. is a scientific advisory board member and has a financial interest in Triplet Therapeutics Inc. His NIH-funded project is using genetic and genomic approaches to uncover other genes that significantly influence when diagnosable symptoms emerge and how rapidly they worsen in Huntington disease. The company is developing new therapeutic approaches to address triplet repeat disorders such Huntington disease, myotonic dystrophy, and spinocerebellar ataxias. His interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. J.F.G. has also been a consultant for Wave Life Sciences USA Inc., Biogen Inc., and Pfizer Inc.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35325614</ArticleId>
        <ArticleId IdType="pmc">PMC9118113</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ajhg.2022.03.004</ArticleId>
        <ArticleId IdType="pii">S0002-9297(22)00100-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>The Huntington’s Disease Collaborative Research Group  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8458085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium  Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease. Cell. 2015;162:516–526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4524551</ArticleId>
            <ArticleId IdType="pubmed">26232222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genetic Modifiers of Huntington’s Disease Consortium  CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease Onset. Cell. 2019;178:887–900.e14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6700281</ArticleId>
            <ArticleId IdType="pubmed">31398342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong E.P., MacDonald M.E., Wheeler V.C., Jones L., Holmans P., Orth M., Monckton D.G., Long J.D., Kwak S., Gusella J.F., Lee J.M. Huntington’s Disease Pathogenesis: Two Sequential Components. J. Huntingtons Dis. 2021;10:35–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7990433</ArticleId>
            <ArticleId IdType="pubmed">33579862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.M., Ramos E.M., Lee J.H., Gillis T., Mysore J.S., Hayden M.R., Warby S.C., Morrison P., Nance M., Ross C.A., et al.  CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012;78:690–695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3306163</ArticleId>
            <ArticleId IdType="pubmed">22323755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bates G.P., Dorsey R., Gusella J.F., Hayden M.R., Kay C., Leavitt B.R., Nance M., Ross C.A., Scahill R.I., Wetzel R., et al.  Huntington disease. Nat. Rev. Dis. Primers. 2015;1:15005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27188817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marxreiter F., Stemick J., Kohl Z. Huntingtin Lowering Strategies. Int. J. Mol. Sci. 2020;21:2146.</Citation>
        </Reference>
        <Reference>
          <Citation>Tabrizi S.J., Leavitt B.R., Landwehrmeyer G.B., Wild E.J., Saft C., Barker R.A., Blair N.F., Craufurd D., Priller J., Rickards H., et al.  Targeting Huntingtin Expression in Patients with Huntington’s Disease. N. Engl. J. Med. 2019;380:2307–2316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31059641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Djoussé L., Knowlton B., Hayden M., Almqvist E.W., Brinkman R., Ross C., Margolis R., Rosenblatt A., Durr A., Dode C., et al.  Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am. J. Med. Genet. A. 2003;119A:279–282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12784292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., Marder K., Penchaszadeh G., Roberts S.A., Gayán J., et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc. Natl. Acad. Sci. USA. 2004;101:3498–3503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC373491</ArticleId>
            <ArticleId IdType="pubmed">14993615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J.L., Hayden M.R., Almqvist E.W., Brinkman R.R., Durr A., Dodé C., Morrison P.J., Suchowersky O., Ross C.A., Margolis R.L., et al.  A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am. J. Hum. Genet. 2003;73:682–687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1180695</ArticleId>
            <ArticleId IdType="pubmed">12900792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorsey E., Huntington Study Group COHORT Investigators  Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS ONE. 2012;7:e29522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3281013</ArticleId>
            <ArticleId IdType="pubmed">22359536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huntington Study Group PHAROS Investigators  At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch. Neurol. 2006;63:991–996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16831969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orth M., Handley O.J., Schwenke C., Dunnett S., Wild E.J., Tabrizi S.J., Landwehrmeyer G.B., European Huntington’s Disease Network  Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY. J. Neurol. Neurosurg. Psychiatry. 2011;82:1409–1412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21097549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paulsen J.S., Hayden M., Stout J.C., Langbehn D.R., Aylward E., Ross C.A., Guttman M., Nance M., Kieburtz K., Oakes D., et al.  Preparing for preventive clinical trials: the Predict-HD study. Arch. Neurol. 2006;63:883–890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16769871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landwehrmeyer G.B., Fitzer-Attas C.J., Giuliano J.D., Gonçalves N., Anderson K.E., Cardoso F., Ferreira J.J., Mestre T.A., Stout J.C., Sampaio C. Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington’s Disease. Mov. Disord. Clin. Pract. (Hoboken) 2016;4:212–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6174428</ArticleId>
            <ArticleId IdType="pubmed">30363395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huntington Study Group  Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov. Disord. 1996;11:136–142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8684382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAllister B., Gusella J.F., Landwehrmeyer G.B., Lee J.M., MacDonald M.E., Orth M., Rosser A.E., Williams N.M., Holmans P., Jones L., Massey T.H., REGISTRY Investigators of the European Huntington’s Disease Network  Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease. Neurology. 2021;96:e2395–e2406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8166441</ArticleId>
            <ArticleId IdType="pubmed">33766994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long J.D., Langbehn D.R., Tabrizi S.J., Landwehrmeyer B.G., Paulsen J.S., Warner J., Sampaio C. Validation of a prognostic index for Huntington’s disease. Mov. Disord. 2017;32:256–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5318276</ArticleId>
            <ArticleId IdType="pubmed">27892614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moss D.J.H., Pardiñas A.F., Langbehn D., Lo K., Leavitt B.R., Roos R., Durr A., Mead S., Holmans P., Jones L., Tabrizi S.J., TRACK-HD investigators. REGISTRY investigators  Identification of genetic variants associated with Huntington’s disease progression: a genome-wide association study. Lancet Neurol. 2017;16:701–711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28642124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schobel S.A., Palermo G., Auinger P., Long J.D., Ma S., Khwaja O.S., Trundell D., Cudkowicz M., Hersch S., Sampaio C., et al.  Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89:2495–2502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5729794</ArticleId>
            <ArticleId IdType="pubmed">29142089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoulson I., Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979;29:1–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">154626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taliun D., Harris D.N., Kessler M.D., Carlson J., Szpiech Z.A., Torres R., Taliun S.A.G., Corvelo A., Gogarten S.M., Kang H.M., et al.  Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021;590:290–299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7875770</ArticleId>
            <ArticleId IdType="pubmed">33568819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loh P.R., Danecek P., Palamara P.F., Fuchsberger C., A Reshef Y., K Finucane H., Schoenherr S., Forer L., McCarthy S., Abecasis G.R., et al.  Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet. 2016;48:1443–1448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5096458</ArticleId>
            <ArticleId IdType="pubmed">27694958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braisch U., Hay B., Muche R., Rothenbacher D., Landwehrmeyer G.B., Long J.D., Orth M., REGISTRY Investigators of the European Huntington’s Disease Network and COHORT Investigators of the Huntington Study Group  Identification of extreme motor phenotypes in Huntington’s disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2017;174:283–294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27868347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braisch U., Muche R., Rothenbacher D., Landwehrmeyer G.B., Long J.D., Orth M., REGISTRY Investigators of the European Huntington’s Disease Network and COHORT Investigators of the Huntington Study Group  Identification of symbol digit modality test score extremes in Huntington’s disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2019;180:232–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30788902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geraci M. Linear quantile mixed models: The lqmm package for Laplace quantile regression. J. Stat. Softw. 2014;57:1–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4230496</ArticleId>
            <ArticleId IdType="pubmed">25400517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warner J.P., Barron L.H., Brock D.J. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington’s disease chromosomes. Mol. Cell. Probes. 1993;7:235–239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8366869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leeuw C.A., Mooij J.M., Heskes T., Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 2015;11:e1004219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4401657</ArticleId>
            <ArticleId IdType="pubmed">25885710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 2005;102:15545–15550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1239896</ArticleId>
            <ArticleId IdType="pubmed">16199517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X., Stephens M. Genome-wide efficient mixed-model analysis for association studies. Nat. Genet. 2012;44:821–824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3386377</ArticleId>
            <ArticleId IdType="pubmed">22706312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aulchenko Y.S., Struchalin M.V., van Duijn C.M. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics. 2010;11:134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846909</ArticleId>
            <ArticleId IdType="pubmed">20233392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson C.H. flexsurv: A Platform for Parametric Survival Modeling in R. J. Stat. Softw. 2016;70:i08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5868723</ArticleId>
            <ArticleId IdType="pubmed">29593450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bates D., Mächler M., Bolker B., Walker S. Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 2015;67:1–48.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim K.H., Hong E.P., Shin J.W., Chao M.J., Loupe J., Gillis T., Mysore J.S., Holmans P., Jones L., Orth M., et al.  Genetic and Functional Analyses Point to FAN1 as the Source of Multiple Huntington Disease Modifier Effects. Am. J. Hum. Genet. 2020;107:96–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7332667</ArticleId>
            <ArticleId IdType="pubmed">32589923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pêcheux C., Mouret J.F., Dürr A., Agid Y., Feingold J., Brice A., Dodé C., Kaplan J.C. Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes. J. Med. Genet. 1995;32:399–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1050439</ArticleId>
            <ArticleId IdType="pubmed">7616551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gellera C., Meoni C., Castellotti B., Zappacosta B., Girotti F., Taroni F., DiDonato S. Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene. Am. J. Hum. Genet. 1996;59:475–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1914734</ArticleId>
            <ArticleId IdType="pubmed">8755937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciosi M., Maxwell A., Cumming S.A., Hensman Moss D.J., Alshammari A.M., Flower M.D., Durr A., Leavitt B.R., Roos R.A.C., Holmans P., et al.  A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine. 2019;48:568–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6838430</ArticleId>
            <ArticleId IdType="pubmed">31607598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Z.Q., Gottlieb B., Beitel L.K., Wong N., Gordon P.H., Wang Q., Puisieux A., Foulkes W.D., Trifiro M. Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. Hum. Mutat. 2002;19:108–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11793469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flower M., Lomeikaite V., Ciosi M., Cumming S., Morales F., Lo K., Hensman Moss D., Jones L., Holmans P., Monckton D.G., et al.  MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1. Brain. 2019;142:1876–1886.</Citation>
        </Reference>
        <Reference>
          <Citation>Gregory S., Crawford H., Seunarine K., Leavitt B., Durr A., Roos R.A.C., Scahill R.I., Tabrizi S.J., Rees G., Langbehn D., Orth M. Natural biological variation of white matter microstructure is accentuated in Huntington’s disease. Hum. Brain Mapp. 2018;39:3516–3527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6099203</ArticleId>
            <ArticleId IdType="pubmed">29682858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright G.E.B., Caron N.S., Ng B., Casal L., Casazza W., Xu X., Ooi J., Pouladi M.A., Mostafavi S., Ross C.J.D., Hayden M.R. Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease. Hum. Mol. Genet. 2020;29:2788–2802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7530525</ArticleId>
            <ArticleId IdType="pubmed">32898862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fox L.M., Kim K., Johnson C.W., Chen S., Croce K.R., Victor M.B., Eenjes E., Bosco J.R., Randolph L.K., Dragatsis I., et al.  Huntington’s Disease Pathogenesis Is Modified In Vivo by Alfy/Wdfy3 and Selective Macroautophagy. Neuron. 2020;105:813–821.e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7060123</ArticleId>
            <ArticleId IdType="pubmed">31899071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin D.D., Ladha S., Ehrnhoefer D.E., Hayden M.R. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 2015;38:26–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25282404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.M., Chao M.J., Harold D., Abu Elneel K., Gillis T., Holmans P., Jones L., Orth M., Myers R.H., Kwak S., et al.  A modifier of Huntington’s disease onset at the MLH1 locus. Hum. Mol. Genet. 2017;26:3859–3867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6455020</ArticleId>
            <ArticleId IdType="pubmed">28934397</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
